Flow cytometry is a technique for detecting and quantifying the physical and chemical properties of a population of cells or particles. A sample containing cells or particles is suspended in a fluid and injected into the flow cytometer equipment in this process. Flow cytometry is a well-established technology for identifying cells in a solution that is most typically used to assess peripheral blood, bone marrow, and other bodily fluids. Immune cells are identified and quantified using flow cytometry, which is also used to describe hematological malignancies. The evaluation of cells through this technique has a key role in diagnosing many chronic diseases. It analyzes biological activities inside cells, apoptosis, necrosis, cell cycle, cell membrane, cell proliferation, and measurement of DNA per cell.
The major diagnostic applications include benign hematologic process, cancer, AIDS, immune deficiency, benign hematologic, and these diseases' detection using fluorescence. In this process, cells are dyed with fluorophores to detect the light emitted to produce the intensity by labeling specific proteins (immunophenotyping) for diagnosing leukemia and lymphomas.
The increasing prevalence of chronic diseases has created a growing demand for flow cytometric techniques that can help researchers and clinicians better understand the underlying mechanisms of these diseases and develop more effective treatments.
Access Full Report @ https://www.databridgemarketresearch.com/es/reports/north-america-flow-cytometry-market
Data Bridge Market Research analyzes that the North America Flow Cytometry Market is expected to reach USD 7.77 billion by 2032 from USD 3.40 billion in 2024, growing at a CAGR of 10.8% in the forecast period of 2025 to 2032.
Key Findings of the Study
Increasing Application of Cytometry Instruments
Flow cytometry instruments have become an integral part of drug discovery and development in the pharmaceutical and biotechnology industries. The development of new flow cytometry equipment has helped researchers analyze and sort cells faster, more accurately and more efficiently, which has helped speed up the drug development timeline. For instance, Beckman Coulter, a leading manufacturer of flow cytometry equipment, has developed the CytoFLEX LX flow cytometer with rapid detection, enhanced sensitivity and a small footprint. CytoFLEX LX is designed to help researchers analyze rare cell populations faster and more efficiently.
Overall, the development of new flow cytometry devices is helping pharmaceutical and biotechnology companies accelerate drug development timelines by enabling faster and more accurate analysis of complex cell populations. With the rising geriatric population and chronic disease cases, the growth of biotechnology and pharmaceutical firms is also expanding. Across the globe, research and development activities are escalating due to public health expenditure with economic performance.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2025 to 2032
|
|
Base Year
|
2024
|
|
Historic Year
|
2023 (Customizable 2013-2017)
|
|
Quantitative Units
|
Revenue in USD Billion
|
|
Segments Covered
|
Product (Reagents and Consumables, Flow Cytometry Instruments, Accessories, Services, and Software), Technology (Cell-Based Flow Cytometry and Bead-Based Flow Cytometry), Application (Research Applications, Clinical Applications, and Industrial Applications), End User (Pharmaceuticals and Biotechnology Companies, Academic & Research Institutes, Hospitals, Clinical Testing Laboratories, CRO, Blood Bank, CMO & CDMO, Forensic Laboratories, and Others), Distribution Channel (Retail Sales and Direct Tenders)
|
|
Countries Covered
|
U.S., Canada , and Mexico
|
|
Market Players Covered
|
BD (U.S.), Agilent Technologies, Inc.(U.S.), Thermo Fisher Scientific Inc.(U.S.), Bio-Rad Laboratories, Inc.(U.S.), Sartorius AG (Germany), BennuBio Inc. (U.S.), Enzo Biochem Inc. (U.S.), Beckman Coulter, Inc. (A Subsidiary of Danaher Corporation) (U.S.), BIOMÉRIEUX (France), Coherent Corp. (U.S.), BioLegend, Inc. (U.S.), Cell Signaling Technology, Inc. (U.S.), Cytek Biosciences (U.S.), Diasorin S.p.A. (Italy), Elabscience Bionovation Inc. (U.S.), Miltenyi Biotec (Japan), Merck KGaA (Germany), NanoCellect Biomedical (U.S.), NeoGenomics Laboratories (U.S.), On-chip Biotechnologies Co., Ltd. Corporation (Japan), ORLFO Technologies (U.S.), Stratedigm, Inc (U.S.), Sony Biotechnology Inc. (U.S.), Sysmex Asia Pacific Pte Ltd (Part of Sysmex Corporation) (U.S.), Union Biometrica, Inc. (U.S.), Apogee Flow Systems Ltd. (U.K.), and Cytonome/ST LLC (U.S.) among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis
The North America flow cytometry markets segmented into five notable segments based on product, technology, application, end user, and distribution channel.
- On the basis of product, the North America flow cytometry market is segmented into reagents and consumables, flow cytometry instruments, accessories, services, and software
In 2025, the reagents and consumables segment is expected to dominate the North America flow cytometry market
In 2025, the reagents and consumables segment is expected to dominate the market with a market share of 53.34% due to the reagents and consumables segment is expected to dominate due to their essential role in medical and research applications. Frequent use, recurring purchases, and the need for consistent, high-quality supplies for procedures and diagnostics drive the demand, contributing to their large market share.
- On the basis of technology, the North America flow cytometry market is segmented into cell-based flow cytometry and bead-based flow cytometry
In 2025, the cell-based flow cytometry segment is expected to dominate the North America flow cytometry market
In 2025, the cell-based flow cytometry segment is expected to dominate the market with a market share of 62.75% due to the cell-based flow cytometry segment is expected to dominate due to its crucial role in analyzing cellular characteristics, aiding in precise diagnostics and personalized treatments. Its widespread use in immunology, cancer research, and drug development contributes significantly to its large market share, driven by increasing demand for advanced research tools.
- On the basis of application, the North America flow cytometry market is segmented into research applications, clinical applications, and industrial applications. In 2025, the research applications segment is expected to dominate the market with a market share of 53.86%
- On the basis of end user, the North America flow cytometry market is segmented into pharmaceuticals and biotechnology companies, academic & research institutes, hospitals, clinical testing laboratories, CRO, blood bank, CMO & CDMO, forensic laboratories, and others. In 2025, the pharmaceuticals and biotechnology companies segment is expected to dominate the market with a market share of 30.98%
- On the basis of distribution channel, the North America flow cytometry market is segmented into retail sales and direct tenders. In 2025, the retail sales segment is expected to dominate the market with a market share of 55.39%
Major Players
Data Bridge Market Research analyzes BD (U.S.), Agilent Technologies, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), and Sartorius AG (Germany) as the major North America flow cytometry market players.
Market Developments
- In July 2024, Agilent Technologies has announced the acquisition of Canadian drug services firm BioVectra for USD 925 million. This move expands Agilent's capabilities in gene editing, specifically in manufacturing oligonucleotides and peptides, enhancing its role in RNA-based therapies and gene editing technologies like CRISPR-Cas
- In June 2024, Thermo Fisher celebrated the ribbon-cutting of a 72,500-square-foot expansion at its Middleton campus, which will serve as a laboratory for pharmaceutical testing. The project will create 350 jobs over the next two years, with state tax credits supporting the initiative
- In November 2024, Sartorius Stedim Biotech has opened a new Center for Bioprocess Innovation in Marlborough, Massachusetts, aimed at advancing the development of next-generation therapeutics. The 63,000-square-foot facility will provide process optimization, training, and GMP suites for clinical production starting in 2025
- In March 2024, Beckman Coulter Life Sciences has launched the CytoFLEX nano Flow Cytometer, a breakthrough in nanoparticle analysis that enables detection as small as 40 nm. This system enhances sensitivity, offering up to 50% more data for research into extracellular vesicles and lower-abundance targets
- In March 2024, Beckman Coulter Life Sciences has received FDA 510(k) clearance to distribute its DxFLEX Clinical Flow Cytometer in the U.S. This simplifies high-complexity testing with enhanced sensitivity and automated compensation, making multicolor flow cytometry more accessible and efficient for labs
Regional Analysis
Geographically, the countries covered in the North America flow cytometry market report are the U.S., Canada, and Mexico.
As per Data Bridge Market Research analysis:
U.S. is the dominating country in the North America flow cytometry market
The U.S. is the dominating country in the North America flow cytometry market due to its advanced healthcare infrastructure, significant research funding, and high concentration of leading biotechnology and pharmaceutical companies. Additionally, the country's focus on precision medicine and growing healthcare investments drive demand for flow cytometry technologies.
Canada is the fastest-growing country in the North America flow cytometry market
Canada is the fastest-growing country in the North America flow cytometry market, driven by increased investments in research and healthcare advancements. The country's growing focus on personalized medicine, expanding biotech sector, and increasing adoption of flow cytometry in academic and clinical settings contribute to its rapid market growth.
For more detailed information about the North America flow cytometry market report, click here – https://www.databridgemarketresearch.com/es/reports/north-america-flow-cytometry-market
